ClinicalTrials.gg
CompletedNCT00644332Updated Jul 2, 2012Results posted

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

A Phase 4 interventional study of Ranolazine in Chronic Angina, sponsored by Gilead Sciences. Completed at 29 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-02.

Sponsored by Gilead Sciences · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
172
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

According to the American Heart Association (AHA) 2011 update of heart disease and stroke statistics, more than 9 million adult patients in the United States (US) have angina. This update also notes that a study of 4 national cross-sectional health examination studies found that, among Americans 40 to 74 years of age, the age-adjusted prevalence of angina was higher among women than men. Per ACC/AHA guidelines, the goal of antianginal therapy is the complete or near complete elimination of anginal chest pain and a return to normal activities and functional capacity. However, evaluating angina and responses to antianginal therapy is often not straightforward. This is particularly true of female patients with angina. Because angina and response to antianginal therapy may differ in men and women, an instrument designed specifically to address symptomatology in women with angina could enhance our understanding and characterization of angina and responses to therapy in this population. The current study will evaluate the validity, reliability, and responsiveness of the newly developed Women's Ischemia Symptom Questionnaire (WISQ) based on changes in angina symptomatology in a female angina population treated with ranolazine, compared with the widely used Seattle Angina Questionnaire (SAQ).

02

Conditions studied

  • Chronic Angina
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 3 months of documented history of stable angina or angina equivalents that is relieved by rest and/or sublingual NTG
  • Taking antianginal therapy with beta-blockers, and/or dihydropyridine calcium antagonists, and/or long-acting nitrates for at least 4 weeks
  • Mean angina frequency of ≥ 2 attacks per week
  • Documented clinical evidence of ischemia

Exclusion criteria

Exclusion Criteria:

  • hepatic impairment
  • Uncontrolled clinically significant cardiac arrhythmias or a history of ventricular fibrillation, torsades de points, or other life-threatening ventricular arrhythmias not associated with acute coronary syndrome
  • Treatment with strong cytochrome P450 inhibitors including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, or saquinavir
  • Prior treatment with ranolazine
  • End-stage renal disease requiring dialysis
  • Myocardial infarction or unstable angina
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
172 participants (actual)

Interventions

  • Oral dosage form.

    Also known as: Ranexa

06

What researchers measure

Primary outcomes

  1. Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and Following Treatment With Ranolazine Assessed as Coefficient of Determination (R^2)

    Validity of the WISQ was assessed by regression analysis. Results of this analysis are reported as the estimated coefficient of determination (R\^2) of the WISQ Total Score at 4 weeks regressed on 4-week angina frequency, 4-week NTG use, and DASI score at 4 weeks. For mean (SEM) Baseline and Week 4 values for angina frequency and NTG use, please refer to Secondary Outcome Measures 7 and 8. For mean (SEM) Baseline and Week 4 DASI values, please refer to Secondary Outcome Measure 9.

    Time frame: Baseline to Week 4

  2. Evaluate the Reliability of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed as Cronbach's Alpha Value

    Reliability of the WISQ was assessed by estimating Cronbach's alpha (standardized); values of 0.7 or higher were to be considered adequate. (Standardized Cronbach's alpha is a coefficient of reliability or consistency, and is a function of the average inter-item correlation.) Cronbach's alpha was calculated for the WISQ instrument overall and for the Angina Frequency/Severity and Angina Stability subscales. Missing item responses were not imputed.

    Time frame: Baseline to Week 4

  3. Evaluate the Responsiveness of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed by Regression Analysis

    Responsiveness of the WISQ was assessed as the estimated coefficient of determination (R\^2) of the change from baseline WISQ Total Score at 4 weeks regressed on change from baseline angina frequency and change from baseline NTG use. For mean (SEM) Baseline and Week 4 values for angina frequency and NTG use, please refer to Secondary Outcome Measures 7 and 8.

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Determine Whether the WISQ is Noninferior to the Seattle Angina Questionnaire (SAQ) With Regard to Angina Frequency Items Based on Changes From Baseline (BL) in the Angina Frequency Items of the WISQ With the SAQ Following Ranolazine Treatment

    Changes from BL in angina frequency items following ranolazine treatment were measured. Analysis: multiple linear regression; response variable: ΔWISQ - ΔSAQ; independent variables: age and BL WISQ and SAQ scores. WISQ items: 15 points (higher=more severe state); SAQ items: 12 points (lower=more severe state). WISQ scores were recalibrated by multiplying by .75. Noninferiority was to be considered demonstrated if the lower limit of a 2-sided 95% CI for WISQ mean - SAQ mean was above the prespecified margin (WISQ vs SAQ difference of -2).

    Time frame: Baseline to 4 Weeks

  2. Compare Changes From Baseline (BL) in the Physical Limitation Items of the WISQ With the SAQ Following Ranolazine Treatment

    Changes from BL in stress, excitement, temperature, satiety, anger, and other limitation items following ranolazine treatment were measured. Analysis: multiple linear regression; response variable: ΔWISQ - ΔSAQ; independent variables: age and BL WISQ and SAQ scores. WISQ items: 27 points (higher=more severe state); SAQ items: 45 points (lower=more severe state). WISQ scores were recalibrated by multiplying by 15/27. Noninferiority was to be considered demonstrated if the lower limit of a 2-sided 95% CI for WISQ mean - SAQ mean was above the prespecified margin (WISQ vs SAQ difference of -2).

    Time frame: Baseline to 4 Weeks

  3. Compare Changes From Baseline (BL) in Other Like Items of the WISQ With the SAQ Following Ranolazine Treatment

    Changes from BL in stress, excitement, temperature, satiety, anger, and other limitation items following ranolazine treatment were measured. Analysis: multiple linear regression; response variable: ΔWISQ - ΔSAQ; independent variables: age and BL WISQ and SAQ scores. WISQ items: 27 points (higher=more severe state); SAQ items: 45 points (lower=more severe state). WISQ scores were recalibrated by multiplying by 15/27. Noninferiority was to be considered demonstrated if the lower limit of a 2-sided 95% CI for WISQ mean - SAQ mean was above the prespecified margin (WISQ vs SAQ difference of -2).

    Time frame: Baseline to 4 Weeks

  4. Determine the Effect of Ranolazine on Angina Frequency as Measured by Patient-reported Diaries

    Angina episodes were recorded by subjects in their diaries. Weekly frequency of angina episodes was calculated for the two-week baseline period and the last two weeks of the study.

    Time frame: Baseline to Week 4

  5. Determine the Effect of Ranolazine on Nitroglycerin Consumption as Measured by Patient-reported Diaries

    Nitroglycerin use was recorded by subjects in their diaries. Weekly frequency of NTG use was calculated for the two-week baseline period and the last two weeks of the study.

    Time frame: Baseline to Week 4

  6. Determine Changes From Baseline in the Duke Activity Status Index (DASI) Following Ranolazine Treatment

    The DASI was analyzed as mean values at baseline and Week 4. The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity).

    Time frame: Baseline to Week 4

  7. Evaluate the Degree of Correlation Between Changes From Baseline in Items of the WISQ and SAQ With Changes From Baseline in Angina Frequency and NTG Diary Data and the DASI

    The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity). The planned analysis was the amount of variation in WISQ and SAQ score changes from baseline explained by changes in angina frequency, NTG use, and DASI score assessed by multiple linear regression analysis.

    Time frame: Baseline to Week 4

07

Results

Posted Jul 2, 2012
Limitations and caveats
The study was terminated early at 86% of targeted enrollment (172 of approximately 200 subjects).

Participant flow

Patients were enrolled at a total of 30 study sites in the US. The first patient was screened on 07 November 2007, and the last patient was screened on 06 December 2010. The last patient observation was on 20 January 2011.

Participant flow — Overall Study
MilestoneRanolazine
Started171
Completed150
Not completed21
Withdrew: Adverse event11
Withdrew: Withdrawal by subject6
Withdrew: Completion status unknown2
Withdrew: Did not meet eligibility requirements1
Withdrew: Could not attend scheduled visits1

Outcome measures

SecondaryDetermine Whether the WISQ is Noninferior to the Seattle Angina Questionnaire (SAQ) With Regard to Angina Frequency Items Based on Changes From Baseline (BL) in the Angina Frequency Items of the WISQ With the SAQ Following Ranolazine Treatment

Changes from BL in angina frequency items following ranolazine treatment were measured. Analysis: multiple linear regression; response variable: ΔWISQ - ΔSAQ; independent variables: age and BL WISQ and SAQ scores. WISQ items: 15 points (higher=more severe state); SAQ items: 12 points (lower=more severe state). WISQ scores were recalibrated by multiplying by .75. Noninferiority was to be considered demonstrated if the lower limit of a 2-sided 95% CI for WISQ mean - SAQ mean was above the prespecified margin (WISQ vs SAQ difference of -2).

Time frame:
Baseline to 4 Weeks
Reported as:
Number · ratio of variance
Determine Whether the WISQ is Noninferior to the Seattle Angina Questionnaire (SAQ) With Regard to Angina Frequency Items Based on Changes From Baseline (BL) in the Angina Frequency Items of the WISQ With the SAQ Following Ranolazine Treatment
ratio of varianceRanolazine
Determine Whether the WISQ is Noninferior to the Seattle Angina Questionnaire (SAQ) With Regard to Angina Frequency Items Based on Changes From Baseline (BL) in the Angina Frequency Items of the WISQ With the SAQ Following Ranolazine Treatment-0.035 (-0.36 to 0.29)
SecondaryCompare Changes From Baseline (BL) in the Physical Limitation Items of the WISQ With the SAQ Following Ranolazine Treatment

Changes from BL in stress, excitement, temperature, satiety, anger, and other limitation items following ranolazine treatment were measured. Analysis: multiple linear regression; response variable: ΔWISQ - ΔSAQ; independent variables: age and BL WISQ and SAQ scores. WISQ items: 27 points (higher=more severe state); SAQ items: 45 points (lower=more severe state). WISQ scores were recalibrated by multiplying by 15/27. Noninferiority was to be considered demonstrated if the lower limit of a 2-sided 95% CI for WISQ mean - SAQ mean was above the prespecified margin (WISQ vs SAQ difference of -2).

Time frame:
Baseline to 4 Weeks
Reported as:
Number · SAQ scale units
Compare Changes From Baseline (BL) in the Physical Limitation Items of the WISQ With the SAQ Following Ranolazine Treatment
SAQ scale unitsRanolazine
Compare Changes From Baseline (BL) in the Physical Limitation Items of the WISQ With the SAQ Following Ranolazine Treatment12.2 (11.3 to 13.2)
SecondaryCompare Changes From Baseline (BL) in Other Like Items of the WISQ With the SAQ Following Ranolazine Treatment

Changes from BL in stress, excitement, temperature, satiety, anger, and other limitation items following ranolazine treatment were measured. Analysis: multiple linear regression; response variable: ΔWISQ - ΔSAQ; independent variables: age and BL WISQ and SAQ scores. WISQ items: 27 points (higher=more severe state); SAQ items: 45 points (lower=more severe state). WISQ scores were recalibrated by multiplying by 15/27. Noninferiority was to be considered demonstrated if the lower limit of a 2-sided 95% CI for WISQ mean - SAQ mean was above the prespecified margin (WISQ vs SAQ difference of -2).

Time frame:
Baseline to 4 Weeks
Reported as:
Number · SAQ scale units
Compare Changes From Baseline (BL) in Other Like Items of the WISQ With the SAQ Following Ranolazine Treatment
SAQ scale unitsRanolazine
Compare Changes From Baseline (BL) in Other Like Items of the WISQ With the SAQ Following Ranolazine Treatment-6.0 (-6.4 to -5.7)
PrimaryEvaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and Following Treatment With Ranolazine Assessed as Coefficient of Determination (R^2)

Validity of the WISQ was assessed by regression analysis. Results of this analysis are reported as the estimated coefficient of determination (R\^2) of the WISQ Total Score at 4 weeks regressed on 4-week angina frequency, 4-week NTG use, and DASI score at 4 weeks. For mean (SEM) Baseline and Week 4 values for angina frequency and NTG use, please refer to Secondary Outcome Measures 7 and 8. For mean (SEM) Baseline and Week 4 DASI values, please refer to Secondary Outcome Measure 9.

Time frame:
Baseline to Week 4
Reported as:
Number · coefficient of determination
Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and Following Treatment With Ranolazine Assessed as Coefficient of Determination (R^2)
coefficient of determinationRanolazine
Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and Following Treatment With Ranolazine Assessed as Coefficient of Determination (R^2)0.337
SecondaryDetermine the Effect of Ranolazine on Angina Frequency as Measured by Patient-reported Diaries

Angina episodes were recorded by subjects in their diaries. Weekly frequency of angina episodes was calculated for the two-week baseline period and the last two weeks of the study.

Time frame:
Baseline to Week 4
Reported as:
Mean · attacks per week
Determine the Effect of Ranolazine on Angina Frequency as Measured by Patient-reported Diaries
attacks per weekRanolazine
Baseline7.9 ± 0.7
Week 43.2 ± 0.6
Statistical analysis
  • Ranolazine · Mean difference (net): -4.7
SecondaryDetermine the Effect of Ranolazine on Nitroglycerin Consumption as Measured by Patient-reported Diaries

Nitroglycerin use was recorded by subjects in their diaries. Weekly frequency of NTG use was calculated for the two-week baseline period and the last two weeks of the study.

Time frame:
Baseline to Week 4
Reported as:
Mean · uses per week
Determine the Effect of Ranolazine on Nitroglycerin Consumption as Measured by Patient-reported Diaries
uses per weekRanolazine
Baseline4.3 ± 0.5
Week 41.1 ± 0.2
Statistical analysis
  • Ranolazine · Mean difference (net): -3.2
SecondaryDetermine Changes From Baseline in the Duke Activity Status Index (DASI) Following Ranolazine Treatment

The DASI was analyzed as mean values at baseline and Week 4. The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity).

Time frame:
Baseline to Week 4
Reported as:
Mean · DASI scale units
Determine Changes From Baseline in the Duke Activity Status Index (DASI) Following Ranolazine Treatment
DASI scale unitsRanolazine
Baseline23.9 ± 1.1
Week 426.8 ± 1.1
Statistical analysis
  • Ranolazine · Mean difference (net): 2.9
PrimaryEvaluate the Reliability of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed as Cronbach's Alpha Value

Reliability of the WISQ was assessed by estimating Cronbach's alpha (standardized); values of 0.7 or higher were to be considered adequate. (Standardized Cronbach's alpha is a coefficient of reliability or consistency, and is a function of the average inter-item correlation.) Cronbach's alpha was calculated for the WISQ instrument overall and for the Angina Frequency/Severity and Angina Stability subscales. Missing item responses were not imputed.

Time frame:
Baseline to Week 4
Reported as:
Number · ratio of variances
Evaluate the Reliability of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed as Cronbach's Alpha Value
ratio of variancesRanolazine
WISQ Overall0.851
WISQ Angina Stability0.308
WISQ Angina Frequency0.794
PrimaryEvaluate the Responsiveness of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed by Regression Analysis

Responsiveness of the WISQ was assessed as the estimated coefficient of determination (R\^2) of the change from baseline WISQ Total Score at 4 weeks regressed on change from baseline angina frequency and change from baseline NTG use. For mean (SEM) Baseline and Week 4 values for angina frequency and NTG use, please refer to Secondary Outcome Measures 7 and 8.

Time frame:
Baseline to Week 4
Reported as:
Number · coefficient of determination
Evaluate the Responsiveness of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed by Regression Analysis
coefficient of determinationRanolazine
Evaluate the Responsiveness of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed by Regression Analysis0.080
SecondaryEvaluate the Degree of Correlation Between Changes From Baseline in Items of the WISQ and SAQ With Changes From Baseline in Angina Frequency and NTG Diary Data and the DASI

The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity). The planned analysis was the amount of variation in WISQ and SAQ score changes from baseline explained by changes in angina frequency, NTG use, and DASI score assessed by multiple linear regression analysis.

Time frame:
Baseline to Week 4
Reported as:
Number · coefficient of determination

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranolazine—8/171 (4.7%)34/171 (19.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventRanolazine
Chest painGeneral disorders3/171
Acute coronary syndromeCardiac disorders1/171
Angina unstableCardiac disorders1/171
Cardiac failure congestiveCardiac disorders1/171
Non-cardiac chest painGeneral disorders1/171
Urinary tract infectionInfections and infestations1/171
ContusionInjury, poisoning and procedural complications1/171
FallInjury, poisoning and procedural complications1/171
Pubic rami fractureInjury, poisoning and procedural complications1/171
DizzinessNervous system disorders1/171
Most frequent other events
Most frequent other events
EventRanolazine
NauseaGastrointestinal disorders22/171
DizzinessNervous system disorders9/171
HeadacheNervous system disorders9/171

Baseline characteristics

Age Continuous
Age Continuous(years)Ranolazine
Mean64.6 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Ranolazine
Female171
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ranolazine
Asian3
Black20
Caucasian143
Hispanic5
Region of Enrollment
Region of Enrollment(participants)Ranolazine
United States171
Body Mass Index
Body Mass Index(kg/m^2)Ranolazine
Mean29.5 ± 6.3
Weight
Weight(kg)Ranolazine
Mean76.7 ± 17.6
08

Study locations

29 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294-0007, United States
  • Cardiovascular Consultants, Ltd.
    Phoenix, Arizona 85032, United States
  • Cardiology Consultants of Orange County
    Anaheim, California 92801, United States
  • Access Clinical Trials/Cardiovascular Research Institute (ACT/CVRI)
    Beverly Hills, California 90210, United States
  • Escondido Cardiology Associates
    Escondido, California 92025, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Mission Internal Medical Group
    Mission Viejo, California 92691, United States
  • South Denver Cardiology Associates, PC
    Littleton, Colorado 80120-5654, United States
  • Guerra Cardiology
    Coral Gables, Florida 33134, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • St. Luke Cardiology Associates
    Jacksonville, Florida 32216, United States
  • Jacksonville Heart Center, PA
    Jacksonville, Florida 32250, United States
  • Jacksonville Heart Center, PA
    Jacksonville, Florida 32258, United States
  • Emory University & Grady Health System
    Atlanta, Georgia 30303, United States
  • Mercy Physician Group Cardiology
    Nampa, Idaho 83686, United States
  • North Shore Cardiology
    Bannockburn, Illinois 60015, United States
  • Gateway Cardiology, P.C.
    Jerseyville, Illinois 62052, United States
  • Northern Indiana Research Alliance
    Fort Wayne, Indiana 46804, United States
  • Ashland Hospital Corporation d/b/a King's Daughters Medical Center
    Ashland, Kentucky 41101, United States
  • University of Louisville, Division of Cardiovascular Medicine
    Louisville, Kentucky 40202, United States
  • Gateway Cardiology, P.C.
    St. Louis, Missouri 63128, United States
  • Integrated Cardiology Consultants, LLC d.b.a. Bryan LGH Heart Institute
    Lincoln, Nebraska 68506, United States
  • Albany Associates in Cardiology
    Albany, New York 12205, United States
  • Total Heart Care, PC
    New York, New York 10128, United States
  • The Lindner Clinical Trial Center
    Cincinnati, Ohio 45219, United States
  • St. Vincent Mercy Medical Center, Cardiac Research
    Toledo, Ohio 43608, United States
  • BlueStem Cardiology
    Bartlesville, Oklahoma 74006, United States
  • Tri-State Medical Group, Cardiology, Sewickley Valley Medical Group, Cardiology
    Beaver, Pennsylvania 15009, United States
  • Cardiology Consultants of Philadelphia
    Philadelphia, Pennsylvania 19111, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2008
First posted
Mar 26, 2008
Start
Nov 2007
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
Jul 2, 2012
Last update
Jul 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00644332
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 26, 2008
Start date
Nov 2007
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Jul 2, 2012
Last update
Jul 2, 2012

Study contacts

Nanette K. Wenger, MD
principal investigator · Emory University
Noel Bairey Merz, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion